- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03317743
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
January 20, 2022 updated by: Idience Co., Ltd.
Open-label, Phase I Clinical Trial to Identify Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Anti-cancer Efficacy of NOV140101(IDX-1197HCl) in Patients With Advanced Solid Tumors
the purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NOV140101 (IDX-1197).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, Phase 1 dose escalation study of NOV140101 (IDX-1197) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of IDX-1197 in patients with advanced solid tumors after failure of standard of care.
DLTs will be assessed as the primary endpoint in this trial.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Songpa-gu
-
Seoul, Songpa-gu, Korea, Republic of, 05505
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥19 year old patients with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors
- Life expectancy ≥12 weeks
- Women of childbearing potential must have a negative pregnancy test outcome
- ECOG performance status ≤2
- Lesions measured by tumor markers or CT/MRI and evaluable according to RECIST v1.1
Patient must have adequate organ function as indicated by the following laboratory values independent of transfusion within 2 weeks:
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9.0g/dL
- Serum creatinine ≤ 1.5×ULN
- Total bilirubin ≤ 1.5×ULN
- AST, ALT ≤ 3×ULN (≤ 5×ULN for patients with liver metastasis or liver cell cancer)
- PT and aPTT ≤ 1.5×ULN
- UPC < 1.0 g/g (one re-test is allowed if positive (≥ 1))
- Patients must provide written informed consent to voluntary participation in this study.
Exclusion Criteria:
- History of hypersensitivity reactions to any of the components of the investigational product or other drugs of the same class
- New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled hypertension (systolic/diastolic blood pressure >140/90mmHg), or other clinically significant cardiovascular abnormalities in the opinion of the investigator
- Uncontrolled cardiac arrhythmia
- Acute coronary syndrome (unstable angina pectoris or myocardial infarction) within the past 6 months
- Major electrocardiogram (ECG) abnormalities in the opinion of the investigator
- Severe infection or severe traumatism
- Pneumonia or respiratory symptoms, such as dyspnea, cough, and fever, requiring treatment and other conditions likely to be accompanied by hypoxemia
- History of drug or alcohol abuse within the past 3 months
- Symptomatic or uncontrolled central nervous system (CNS) metastasis
- Less than 4 weeks have elapsed since a major surgery and 2 weeks have elapsed since a minor surgery
- Radiotherapy, hormone therapy, or chemotherapy within 2 weeks prior to baseline from which toxicities not recovered to ≤grade 1
- >4 weeks of persistent Grade 3 (NCI-CTCAE v4.03) hematologic toxicities from prior anticancer treatment
- History of myelodysplastic syndrome (MDS) or pre-treatment cytogenetic test results indicative of the risk of MDS or acute myelocytic leukemia
- Ongoing or anticipated treatment with antiplatelet drugs (aspirin, clopidogrel, etc.) or anticoagulant drugs (warfarin, heparin, etc.) during the study
- Requiring continuous treatment with systemic NSAIDs or systemic corticosteroids
- Ongoing or past treatment with immunosuppressants within 14 days prior to the first dose of study treatment, except for intranasal, inhaled, topical, or locally injected (e.g., intraarticular injection) steroids
- History of serious gastrointestinal bleedings within 12 weeks prior to screening or presence of diseases that may affect oral drug absorption (e.g., malabsorption syndrome, active peptic ulcer)
- History of human immunodeficiency virus infection or active hepatitis B or C infection or ongoing uncontrolled chronic infectious disease
- Pregnant or lactating women or patients planning to become pregnant during the study
- Participation in another clinical trial within 30 days prior to screening
- Individual considered ineligible for this study for other reasons, in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NOV140101 (IDX-1197)
|
The dose levels will be escalated following a 3+3 dose escalation scheme.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose Limiting Toxicities (DLTs)
Time Frame: Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-21)
|
Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-21)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 29, 2017
Primary Completion (Actual)
December 8, 2020
Study Completion (Actual)
October 13, 2021
Study Registration Dates
First Submitted
October 18, 2017
First Submitted That Met QC Criteria
October 18, 2017
First Posted (Actual)
October 23, 2017
Study Record Updates
Last Update Posted (Actual)
February 3, 2022
Last Update Submitted That Met QC Criteria
January 20, 2022
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NOV140101-101/ID-VDP-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
Clinical Trials on NOV140101 (IDX-1197)
-
Idience Co., Ltd.Completed
-
Idience Co., Ltd.Active, not recruitingSolid Tumors | Homologous Recombination Deficiency | Homologous Recombination Repair Gene MutationKorea, Republic of
-
Idience Co., Ltd.RecruitingGastric CancerKorea, Republic of, United States, China
-
Digital Diagnostics, Inc.The Emmes Company, LLCCompleted
-
Johns Hopkins UniversityJuvenile Diabetes Research Foundation; National Eye Institute (NEI)RecruitingType 1 Diabetes | Type 2 Diabetes | Cystic Fibrosis-related DiabetesUnited States
-
Johns Hopkins UniversityNational Eye Institute (NEI)CompletedType 1 Diabetes | Type 2 DiabetesUnited States
-
Intrinsic LifeSciences, LLCBoston Children's HospitalCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic LymphomaUnited States
-
Narendranath EpperlaWithdrawnRecurrent Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Nodal Marginal Zone Lymphoma | Recurrent Nodal Marginal Zone Lymphoma | Recurrent Splenic Marginal Zone Lymphoma | Refractory Splenic Marginal Zone Lymphoma and other conditions
-
Emory UniversityNational Cancer Institute (NCI); Novartis; Secura Bio, Inc.RecruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell LymphomaUnited States